Day 2 | Saturday, Feb 3, 2018

SATURDAY MORNING SESSION

TUMOR

Time Agenda
8:00 - 8:20 AM An Analysis of Intraoperative MRI Imaging Tumor Volumes Compared with Immediate and 3 Month Postoperative Volumes Correlated with Glioma Tumor Biology and Patient Outcome.
RANDY L. JENSEN, MD, PhD, Salt Lake City, UT
Randy Jensen
8:20 - 8:25 AM Discussion
8:25 - 8:45 AM Prognostic Role of Mitochondrial Pyruvate Carrier in Isocitrate Dehydrogenase–Mutant Glioma.
MICHAEL KARSY, MD, Salt Lake City, UT
Michael Karsy, Jian Guan, L. Eric Huang
8:45 - 8:50 AM Discussion
8:50 - 9:10 AM Hypertonic Saline Versus Mannitol: A Characterization and Comparison of Measured Characteristic.
JONATHAN PERRY SCOVILLE, MD, Salt Lake City, UT
Jonathan Scoville, Greg Hawryluk
9:10 - 9:15 AM Discussion
9:15 - 9:35 AM Hereditary Predisposition to Medulloblastoma - Results of an International Genome Sequencing Project.
DANIEL W. FULTS, MD, Salt Lake City, UT
Dan Fults
9:35 - 9:40 AM Discussion
9:40 - 10:00 AM Technical Nuances in Removal of a Subependymoma and Colloid Cyst via the Transcallosal Interforniceal Approach: Dual Pathology in the Intraventricular System Causing Obstructive Hydrocephalus.
CELINA M. CRISMAN, MD, Salt Lake City, UT
Celina M. Crisman, Elena Solli, James K. Liu
10:00 - 10:05 AM Discussion
10:05 - 10:25 AM Costs and Lessons Learned in Implementing a Minimally Invasive Trans-Sulcal Approach.
MICHAEL KIM, MD, Valhalla, NY
Michael Kim, Christian Bowers, Justin Santarelli, Chirag Gandhi, Meic Schmidt
10:25 - 10:30 AM Discussion
10:30- 11:00 AM KASDON LECTURER
Immunotherapy for Glioma.
JAMES M. MARKERT, M.D., Birmingham, AL
James Markert
11:00 - 11:05 AM Discussion
11:05 AM Adjourn

SATURDAY AFTERNOON SESSION

TUMOR

Time Agenda
4:00 - 4:15 PM Synergistic Meningioma Treatment with PARP Inhibitors, Temozolomide and Radiotherapy.
JONATHAN HARPER, Salt Lake City, UT
Jonathan Harper; Michael Karsy, David Gillespie, Randy Jense
4:15 - 4:20 PM Discussion
4:20 - 4:40PM IDH1 Mutation Drives Tumor Initiation in an RCAS Glioma Model.
HOWARD COLMAN, M.D., Ph.D., Salt Lake City, UT
Howard Colman, Sheri Holman
4:40 - 4:45 PM Discussion
4:45 - 5:05 PM Functional Requirement of a Wild-Type Allele for Mutant IDH1 to Suppress Anchorage-Independent Growth Through Redox Homeostasis.
PATRICIA D.B. TIBURCIO, Ph.D., Salt Lake City, UT
Patricia D. B. Tiburcio, Hai Yan, L. Eric Huang
5:05 - 5:10PM Discussion
5:10 - 5:30 PM Brachytherapy Seeds and Ketogenic Diet: A Better up-front Treatment for GBMs?
KRIS A. SMITH, M.D., Phoenix, AZ
Kris A. Smith
5:30 - 5:35PM Discussion
5:35- 6:05PM From Temozolomide to Tumor Treating Fields, from Immunohistochemistry NGS. Clinical and Translational Research in Glioma.
ROGER STUPP, M.D., Chicago, IL
Roger Stupp
6:05 - 6:10 PM Discussion
6:10 - 6:40 PM The NOMS Approach to Metastatic Spine Tumors: The Rational Integration of Multi-Modality Therapy.
MARK BILSKY, M.D., New York, NY
Mark Bilsky
6:40 - 6:45 PM Discussion
6:45 PM Adjourn
6:45 PM Family Dinner and Heilbrun Lecturer

Contact Us

Lanette Dunbar
Meeting Coordinator
Health Science Center
Bldg 550, 5th Floor
175 N. Medical Drive East
Salt Lake City, UT 84132
Phone: 801-556-2539
Fax: 801-581-4385
Email: lanette.dunbar@hsc.utah.edu